002755 Beijing Aosaikang Pharmaceutical
- 10.54
- -0.20-1.86%
Beijing Aosaikang Pharmaceutical News
Beijing Aosaikang Pharmaceutical: 2024 Interim Performance Forecast
Beijing Aosaikang Pharmaceutical (002755.SZ): Expects a profit of 66 million to 85 million yuan in the first half of the year, achieving a turnaround from losses in the same period last year.
On July 12th, Gelunhui announced that Beijing Aosaikang Pharmaceutical (002755.SZ) released its performance forecast for the first half of 2024. According to preliminary estimates by the financial department, it is expected to achieve a net income of 66 million yuan to 85 million yuan attributable to the shareholders of the listed company in the first half of 2024, compared with a loss of 158.4523 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is 45 million yuan to 58 million yuan, compared with a loss of 183.5443 million yuan in the same period last year. The basic earnings per share are 0.07 yuan/share to 0.09 yuan/share. Reasons for the performance changes: 1. Increase in revenue: the company's anti-infection products...
As of June 20, 2024, the number of shareholders in Beijing Aosaikang Pharmaceutical (002755.SZ) was 19,640.
Beijing Aosaikang Pharmaceutical (002755.SZ) stated on the investor interaction platform on July 5th that as of June 20, 2024, the number of shareholders in the company is 19,640.
Beijing Aosaikang Pharmaceutical (002755.SZ): Subsidiary injection of foscarnet disodium and pyrimethamine obtained pharmaceutical registration certificate.
On July 1st, Gelunhui announced that its wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd. ('the Company'), has recently received from the National Medical Products Administration (NMPA) the registration certificate for the injection of fosaprepitant dimeglumine. Fosaprepitant dimeglumine is a prodrug of aprepitant, and its antiemetic effect comes from aprepitant. Fosaprepitant dimeglumine can be transformed into aprepitant within 30 minutes after intravenous administration. Aprepitant selectively blocks neurokinin-1 (NK-1) receptors, thereby inhibiting chemotherapy-induced vomiting. It is mainly used for prophylaxis.
Osecon (002755.SZ): net loss of 149 million yuan in 2023
On April 28, Ge Longhui (002755.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,443 million yuan, a year-on-year decrease of 22.92%; net loss attributable to shareholders of listed companies was 149 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 227 million yuan; basic loss per share was 0.16 yuan/share.
Osecon (002755.SZ) announced first-quarter results, net profit of 31.5547 million yuan, turning a loss into a profit
According to Zhitong Finance App News, Osecon (002755.SZ) released its report for the first quarter of 2024. The company's operating income was 448 million yuan, up 32.47% year on year; net profit attributable to shareholders of listed companies was 31,5447 million yuan, which turned a loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 235.361 million yuan; basic income per share was 0.03 yuan/share.
Osecon (002755.SZ): The novel CMET inhibitor ASKC202 showed deep tumor remission and sustained anti-tumor signals
Osecon (002755.SZ) issued an announcement. Jiangsu Aosaikang Pharmaceutical Co., Ltd., a subsidiary of the company (hereinafter referred to as...
Osecon (002755.SZ): The subsidiary will present clinical research data for the innovative drug ASKC202 at the 2024 AACR Annual Meeting
Gelonghui, April 8, 丨 Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, first announced phase I (ASKC202-001) dose-increasing clinical trial data in the form of a poster at the American Association for Cancer Research (AACR) annual meeting on April 8, 2024.
Osecon (002755.SZ): Notice of acceptance of the subsidiary's application for drug registration and marketing approval for injectable delafloxacin
Gelonghui (002755.SZ) announced on March 4 that Jiangsu Osecon Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, recently received the “Notice of Acceptance” of the marketing license application for injectable delafloxacin issued by the State Drug Administration. Delafloxacin (delafloxacin) is a next-generation broad-spectrum fluoroquinolone antimicrobial used in acute bacterial skin and structural skin infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Osecon (002755.SZ) issued an advance loss. It is expected to lose a huge loss of 140 million yuan to 200 million yuan in 2023, and the loss will narrow
Osecon (002755.SZ) released the 2023 annual performance forecast, and the company expects 2023 to fall under the above...
Osecon (002755.SZ): Subsidiary torimifene citrate tablets obtained drug registration certificate
Gelonghui, January 22丨Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“Subsidiary”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for torimifene citrate tablets approved and issued by the State Drug Administration. Toremifene is a non-steroidal tristyrene derivative that binds to estrogen receptors in a competitive manner with estrogen to prevent cancer cells from growing. Toremifene citrate tablets were developed by KYOWA KIRIN in Japan, and the trade name is FARESTON (FARESTON). China Pharmaceutical Industry Information Center PDB Drug Comprehensive Count
Osecon (002755.SZ) subsidiary announces the latest research results of the innovative drug ASKB589 at the American Society of Clinical Oncology Symposium
Osecon (002755.SZ) announced that AskGene Limited, a subsidiary of the company...
Osecon (002755.SZ) subsidiary etrapopa ethanolamine tablets obtained a drug registration certificate
Zhitong Finance App News, Osecon (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for etrapoethanolamine tablets approved and issued by the State Drug Administration. The relevant indications are: This product is suitable for adults with chronic immune (idiopathic) thrombocytopenia (ITP) patients with chronic immune (idiopathic) thrombocytopenia (ITP) in children aged 6 and above who have previously had poor response to corticosteroids, immunoglobulins, etc. This product is only used in ITP patients with increased risk of bleeding due to thrombocytopenia and clinical conditions.
Osecon (002755.SZ): The subsidiary's innovative drug ASKC202 tablets and ASK120067 tablets were approved for clinical trials
Gelonghui (002755.SZ) announced that the clinical trial of ASKC202 tablets combined with ASK120067 tablets reported by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“subsidiary”), a wholly-owned subsidiary of the company, recently received a clinical trial approval notice issued by the State Drug Administration. The combined use of ASKC202 tablets and ASK120067 tablets will conduct an open, multi-center, I evaluation of the safety, tolerability, pharmacokinetic characteristics and initial efficacy of ASKC202 tablets in patients with advanced solid tumors Phase clinical trials.
Osecon (002755.SZ): Temozolomide capsules obtained a drug registration certificate
Osaikang (002755.SZ) announced that Jiangsu Aosaikang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received...
Osecon (002755.SZ) released the first three quarter results, with a net loss of 185 million yuan
Osecon (002755.SZ) released its report for the third quarter of 2023, achieving revenue of 11.2 in the first three quarters...
Aosaikang Pharmaceutical's Unit Gets Nod to Test Gastric Cancer Drug
[Instant Analysis of BT Financial Report] Osecon 2023 Interim Report: Facing industry pressure, year-on-year decline in operating income, increase in R&D investment
Osecon (stock code: 002755) is a company engaged in the pharmaceutical manufacturing industry. In the context of facing the challenges of centralized drug procurement and R&D innovation, Osecon's 2023 interim report shows that the company's revenue fell 29.56% year-on-year, mainly due to lower prices of selected products collected. Operating costs increased by 26.93% year-on-year, mainly due to the variety structure. Selling expenses fell 33.67% year over year, mainly due to lower expenses due to lower revenue. Management expenses fell 3.90% year over year, with little change. Financial expenses decreased by 64.99% year on year, mainly
Osecon (002755.SZ): Net loss of 15,800 yuan in the first half of the year
Glonghui, August 30 | Osecon (002755.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 712 million yuan, down 29.56% year on year; net profit attributable to shareholders of listed companies was -15,800 yuan, year-on-year profit to loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -184,000 yuan; basic earnings per share were -0.17 yuan.
Glonhui Announces Selected | Donga Ejiao's net profit of 531 million yuan in the first half of the year increased 72.29% year-on-year; Youhan Silicon says the company was not affected by the earthquake
[Performance Focus] Donga Ejiao (000423.SZ) Performance Report: Net profit for the first half of the year was 531 million yuan, up 72.29% year on year Donga Ejiao (000423.SZ) released the 2023 semi-annual results report. During the reporting period, it achieved total operating income of 2.167 billion yuan, up 18.69% year on year; net profit attributable to shareholders of listed companies was 531 million yuan, up 72.29% year on year. Dongpeng Drinks (605499.SH): Net profit of 1.108 billion yuan in the first half of the year increased by 46.84% year-on-year, Dongpeng Drinks (605499.SH) announced
Analysis
Price Target
No Data
